Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Collaboration enables the development of Aethlons Hemopurifier in tandem with SeaStars cartridges for multiple clinical targets

SeaStars cartridges

Aethlon Medical, Inc. and SeaStar Medical, Inc. announced a cross-licensing agreement to jointly develop their respective medical devices to address the care and management of critically ill patients.

Aethlon Medical is developing the Hemopurifier, a first-in-class blood purification cartridge used to remove a range of different particles from the blood, including cancer promoting exosomes for the treatment of cancers with no adequate alternative therapy and viruses for the treatment of life-threatening viral diseases. SeaStar’s platform of cartridges include the CLR 2.0 Hemofilter which is FDA 510K cleared for acute kidney injury (AKI), congestive heart failure (CHF) and pulmonary edema and is currently being marketed for organ preservation in the solid organ transplant market. Each company’s cartridges are designed to fit onto standard, hospital ICU-based equipment, either independently or together, and the companies plan to jointly develop complete treatment solutions that will allow deployment into multiple inpatient and outpatient treatment settings in any clinical indication where combined use of the Hemopurifier and CPCs may improve or expand indications for use, including but not limited to infectious disease, oncology and organ preservation and transplant.

“The potential synergy of our two companies’ platforms should allow penetration into multiple unaddressed markets,” said Timothy C. Rodell, M.D., Interim Chief Executive Officer of Aethlon Medical. “Many solid organ transplant patients’ outcomes are impacted by viral infections, including hepatitis C and cytomegalovirus (CMV), so the demonstrated ability of the Aethlon Hemopurifier to clear viruses could be complementary to SeaStar’s CLR 2.0’s ability to improve donor organ function. Likewise, inflammation has a role in cancer, which could make the SeaStar products complementary to the Hemopurifier.

Aethlon and SeaStar align on combining their complementary novel medical devices to address critical unmet needs,” said Charles J. Fisher Jr., M.D., Chief Executive Officer of SeaStar Medical. “Combinations of the Hemopurifier and the SeaStar cartridges present unique and promising development paths. After joining Aethlon’s board of directors in November 2017, I realized that both teams are equally passionate about providing innovative medical products designed to improve the survival of patients with cancer, infectious and inflammatory disorders.”

About SeaStar Medical, Inc.
SeaStar Medical’s transformative immune and inflammation modulating technology addresses transplantation, inflammation and oncology. This innovative bedside technology has been shown to be safe in humans and has demonstrated a reduction of inflammation and associated tissue injury in organs. SeaStar’s name is inspired by the sea star, which possesses both unique anti-inflammatory and anti-cancer properties. For more information, visit http://www.seastarmed.com/.

About Aethlon Medical, Inc.
Aethlon Medical is focused on addressing unmet needs in global health. The Aethlon Hemopurifier® is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Company believes that the Hemopurifier depletes the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis, and inhibit the benefit of leading cancer therapies. The Hemopurifier® is an FDA designated “Breakthrough Device” related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed with approved therapies.

Additionally, Aethlon owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression. Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.co

Seasoned medical device company boss Mark Harwood joins Camstent as CEO

Seasoned medical device

Camstent Ltd., the company applying proprietary bacteria-phobic polymer coatings to medical devices, announces the appointment of Mark Harwood as CEO. Mark is a respected figure with an exceptional track record in the medical device sector.

Mark is returning to the UK from Malaysia where he spent two and a half years undertaking consultancy and M&A projects with healthcare businesses in the region. This included transforming a family-run emergency services business into a mid-sized corporation. In the UK, Mark is best known for his time as CEO of PneumaCare, the Cambridge UK-based respiratory monitoring medical imaging company. Here, he developed a range of respiratory products, instigated global clinical studies, published numerous papers and significantly expanded the company’s distribution network and sales.

Mark spent a number of years in the US in leading roles in medical device companies including President and CEO of Arjo Huntleigh, Global Vice President of Baxter International Inc., and President of RF Technologies (North America & EMEA). Prior to this Mark was UK and Ireland Managing Director at Arjo Med AB, a global supplier of medical devices.

Camstent’s founder and CTO, Dave Hampton, said: “We are very fortunate to have Mark join us as Chief Executive Officer. His arrival comes at a critical time for Camstent and the Board believes he will play a pivotal role in the company’s next stage of development. Mark has an outstanding track record of growing small medical device companies into global players as well as managing large teams where he oversees all aspects of a business including sales, marketing and manufacturing. He also has extensive regulatory and quality experience which will be key for us as we look to expand our sales into the US, a market where he has a considerable knowledge.”

Mark Harwood said: “I am joining Camstent at a very exciting time for the business and I am looking forward to working in the UK once again. Camstent’s bacteria-phobic coatings have the potential to become real game-changers in the battle against infections caused by medical devices.

I am eagerly anticipating working with the team to grow the company sales, increase awareness of Camstent’s products, develop customer relationships and reporting on the company’s continued progress to investors.”

About Camstent
Camstent’s mission is to address the problem of hospital-acquired infections that affect 1 in 25 patients (300,000 people in England and 1.7 million in the US). Thirty-eight per cent of these are the result of catheter associated urinary infections, increasing patient morbidity and length of hospital stays. In the US, as many as 99,000 patients die from these infections every year; 37,000 in Europe and almost 10,000 in the UK. After extensive development by Camstent, the bacteria-phobic polymers, which were first discovered at the University of Nottingham in 2012, have been formulated as a coating for catheters and other silicon/silastic medical devices.

Camstent hold accreditation to the internationally recognized quality standard ISO 13485:2016, which states the requirements of the Quality Management System (QMS) for the design and manufacture of Medical Devices.

The Camstent coated catheters offer enhanced lubricity, with the aim or improving patient comfort during catheter insertion and removal. They are CE marked / certified for drainage of urine and are available for sale in the UK and EU.

Delta Electronics Provides Uninterrupted Power Supply at the Research Institute of Childrens Infections in St Petersburg

Delta Electronics Uninterrupted Power Supply

Delta Electronics, the leading provider of switching power supply systems and uninterrupted power solutions, has completed a project installing UPS systems at the facility of Scientific Research Institute of Children’s Infections of the Federal Medical and Biological Agency (FSBI) in St. Petersburg, Russia. The project was completed with the support of Delta Electronics’ partner, Spectr RS.

In today’s Russia, a lot of attention is paid to the modernization of the country’s healthcare system. The government’s targeted programs include implementation of specialized IT solutions that help medical institutions work more efficiently and improve the quality of patient care. One such medical institution is the FSBI. Operating since 1927, it is Russia’s oldest research center for children’s infections research study. Today the Institute is involved both in providing medical assistance to children with infectious diseases and in conducting research that constitutes an invaluable contribution to science and expands our knowledge about the human body.

As part of the latest renovation and modernization of the Institute’s medical facility and the Radiology Diagnostics Department, Delta’s UPS systems were installed for MRI and CT scanners, CCTV systems, fire alarm systems, lighting and smoke exhaust systems in the Institute’s medical facility. The project, carried out from February 2013 till September 2016, covered a total floor area of 29,136.8 square meters.

To meet the objective of ensuring uninterrupted power supply at FSBI, Petrobalt, the general contractor of the renovation, together with specialists representing Spectr RS selected UPS systems manufactured by Delta Electronics: the Ultron family HPH series UPS with capacities of 60 and 120 kVA and the highest efficiency in the segment—up to 96%). These UPS systems are based on digital signal processing (DSP) technology, which helps reduce the number of electronic components and brings down the failure rate, which is extremely important in the work of high-precision medical devices. In addition, the system’s reliability is boosted by the fact that it includes redundant auxiliary power and fans. The watchdog circuit controls the redundant auxiliary power circuit, decreasing the probability of system failure that may be caused by malfunction of any of the elements.

This solution was aimed at increasing the working reliability of expensive magnetic resonance, computed tomography equipment, and the ancillary medical devices in the radiological diagnostics rooms of the medical institution.

At the moment, the UPS systems installed at the Institute can support power to the equipment for 15 minutes during a power outage in the mains. In addition, especially for this project, the contractor produced battery cabinets, which perfectly fit in the limited space at the facility.

“We believe that the solutions developed by Delta Electronics are the best in their class because they offer a combination of maximum available power, unparalleled energy efficiency, and excellent parameters for medical facilities, which require highly reliable power protection systems,” said Darya Borok, marketing specialist at Spectr RS. “In the end, all this will allow the medical centers to work more efficiently and to take better care of their little patients.”

EDC signs deal to supply power to Batangas hospital

LOPEZ-LED Energy Development Corp. (EDC) and the Mary Mediatrix Medical Center (MMMC) signed a contract for the supply of power to the hospital located in Lipa, Batangas.

Under the deal, EDC will supply MMMC 1 megawatt (MW) for two years. Electricity will be sourced from EDC’s BacMan Geothermal Inc.

“This contract symbolizes our commitment not only to our partnership, but also to our environment. It is a good opportunity that First Gen-EDC offered us this alternative energy solution. Not only will we be able to generate substantial savings through this initiative, but we will still be able to deliver high-quality health-care services to our patients without compromise,” MMMC CEO and President Dr. Robert Magsino said at the contract signing held in Lipa, Batangas.

“Geothermal power provides clean, renewable and reliable energy source that allows us to reduce our operation’s negative impact to the environment by reducing our carbon footprint. With this in mind, we look forward to mutually beneficial and strong partnership with First Gen-EDC,” he added.

MMMC has been giving appropriate care to its patients in Southern Luzon since 1994. It received its ISO 9001:2008 certification in 2013, a proof of the hospital’s international quality standards.

EDC is one of the world’s largest geothermal producers and the country’s leading renewable- energy company with an installed capacity of 1,475 MW. For over 40 years, EDC has been implementing comprehensive environmental management programs that enhance the ecosystem and corporate social responsibility programs, ensuring inclusive growth for its partner communities.

Piedmont Henry Hospital Goes Vertical to Improve Patient Wait Times

Piedmont Henry Hospital

Piedmont Henry Hospital recently unveiled brand new, first of its kind in Georgia vertical treatment spaces in the hospital’s emergency department (ED) designed to provide better, faster care for patients.

Known as a vertical model, the hospital converted 10 rooms in the emergency department into 18 treatment spaces fully equipped to expedite care for lower acuity patients and free up much-needed bed capacity for more acutely ill patients. Instead of horizontal stretchers (beds), the vertical treatment spaces feature a comfortable recliner, monitors, oxygen and suction equipment. In addition to ensuring a faster delivery of care, this new treatment model has proven successful in improving patient safety and satisfaction.

“This is major milestone not only for our hospital but also for the Georgia health community,” said Deborah Armstrong, CEO of Piedmont Henry. “Making this investment in our community not only shows Piedmont Henry’s commitment to better serve our patients, it also ensures they have the best possible experience while in our care.”

Piedmont Henry has seen a significant growth in volume over the last several years. As one of the busiest in the state and in the Piedmont Healthcare system, Piedmont Henry’s ED serves close to 90,000 patients each year.

“Nobody plans on going to the ED but if you have to come, you want to leave as soon as possible,” said Dr. William Watkins, ED medical director at Piedmont Henry. “The addition of these vertical treatment spaces allows us to quickly and effectively treat more patients, which helps reduce wait times and length of stay.”

In addition to this project, Piedmont Henry recently added two new operating room suites and a minor procedure room to its Outpatient Surgery Center. Using the latest cutting-edge technology to provide the highest quality of care and services possible, the additional surgical space is expected to improve the efficiency of surgeons and staff, allowing them to perform more procedures in a safe, comfortable and timely manner.

TCS Healthcare Technologies Releases ACUITYnxt 1.5

TCS Healthcare

TCS Healthcare Technologies is excited to release ACUITYnxt 1.5, the latest version of the most intuitive case management software in the industry. ACUITYnxt is a secure cloud-based case management software application that fully supports the case management process.

“Many of today’s case managers are contractors and business owners themselves so time-tracking, capturing billable items, and invoicing are critical features for them,” said Deborah Keller, RN, BSN, Chief Executive Officer for TCS.

Keller notes, “ACUITYnxt now fully supports these needs. Our work logs are designed to support simple time-tracking workflows as well as workflows requiring granular billing documentation for time, units of service, specific medical codes, and user-defined items such as mileage as well. While work logs can be created manually, ACUITYnxt can automatically prompt users with a new work log after saving changes to specific modules or record types.”

In addition to the new time tracking features, ACUITYnxt 1.5 includes several new reports to support invoicing and care plan coordination.

“We have also enhanced a feature unique to ACUITYnxt, drag and drop Screen Templates. Screen Templates allows for customized layouts for key modules without expensive software coding. This feature has been expanded to the Work Log module,” adds Keller. “TCS Healthcare continues to push out new ACUITYnxt functionality in alignment with a very robust road map. Our entire team is excited about our next release this fall which will include population health stratification and workflow automation. Authorization management including grievances and appeals management is very soon to follow.”

Varian to Provide Mobile Technology to Cancer Patients Across Tennessee

Varian  Mobile Technology to Cancer Patients Across Tennessee

Providing cancer patients an opportunity for increased participation in their treatment, Varian  announced its collaboration with Tennessee Oncology for the implementation of Noona, a software application for managing patient symptoms and capturing patient reported outcomes (PROs) in cancer care. As part of this collaboration, Noona will be deployed at more than 30 centers across Tennessee, with the goal of reaching approximately 25,000 patients per year.

The Tennessee Oncology network treats nearly 50 percent of all cancer patients in Tennessee, with a large percentage residing in rural settings. The implementation of Noona will provide these patients with a better way to communicate their symptoms and other relevant clinical information to their care team, while eliminating common barriers to adoption, such as patients’ physical location or technology adeptness.

“We put patients first and seek out technology that goes the extra step. A desirable benefit of Noona’s advanced information intelligence is the ability to more closely connect to our patient’s quality of life and the advantage of aligning care to their changing needs,” said Dr. Natalie Dickson, chief medical officer of Tennessee Oncology. “All patients deserve to receive the best quality of care regardless of where they live, and we are continually seeking ways to make that happen.”

“Leveraging data and information technology hastens our goal of delivering the most advanced care to every newly diagnosed patient, wherever they live,” adds Dr. Jeff Patton, chief executive officer of Tennessee Oncology. “Noona’s outcome data collection pleasantly aligns with our value-based world. Our patients deserve our best.”

“The healthcare industry strives to move from disease-centered to person-centered care—which requires us to capture information that describes the patient experience,” said Corey Zankowski, senior vice president, Oncology Software Solutions, Varian. “Noona helps us achieve this goal by better connecting patients to their personal treatment and enabling clinicians to collect meaningful PRO data to adapt treatments for each patient and to predict future outcomes.”

Noona is structured to collect a standardized dataset that is centered around patients’ quality of life—including new or shifting symptoms that may signal a necessary shift in care. The interface is designed for an optimal user experience and with seamless access in mind. It may be accessed on any device with a web browser or through its native Apple® or Android™ app. Patients are assigned a treatment module that aligns with their cancer type and allows them to regularly report and track their symptoms while sharing their questions and concerns instantly.

Positive outcomes reported from clinics worldwide that have already adopted Noona include:

Increased clinical efficiency and reduced workloads, saving up to 60 minutes per day, per user.
Improved information capture with a 90 percent patient response rate for symptom questionnaires.
More effective patient triage with algorithms that prioritize patients by symptom severity.

Varian and Tennessee Oncology will work closely together through the end of 2019, and beyond, to focus on the continued adoption of the solution across its network.

About Varian
Varian is a leader in developing and delivering cancer care solutions and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 7,000 people around the world.

About Tennessee Oncology
Tennessee Oncology, PLLC is one of the nation’s leading teams of cancer care specialists, nationally recognized for improving patient outcomes and driving quality of life innovation. In 2018 it created a partnership with OneOncology, a technology-powered, data-driven, alliance of America’s foremost community oncologists. Our comprehensive range of cancer care services includes specialized oncology nursing care, laboratory services, pharmacy, outpatient chemotherapy, PET/CT services, palliative care, patient and family education and financial support services. Founded in 1976, our unique vision, introducing patient-driven care with a clinical trial focus, propelled Tennessee Oncology to lead one of the largest, physician-owned, community oncology practices in the country. Currently over 95 physicians in more than 30 locations, share the privilege of serving adult cancer patients from South Central Kentucky through Middle Tennessee to Northwest Georgia. For a complete list of Physicians, locations and services please visit: www.tnoncology.com

Glaukos Corporation Completes Acquisition of DOSE Medical Corporation

industry_reports - 11391-uhg-acquired.jpg

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel ophthalmic surgical devices and sustained pharmaceutical therapies, announced that it has successfully completed the acquisition of DOSE Medical Corporation. With the transaction’s completion, DOSE Medical has now become a wholly owned subsidiary of Glaukos.

DOSE Medical is developing multiple micro-invasive, bioerodible, sustained-release drug delivery platforms designed to be used in the treatment of various retinal diseases, including age-related macular degeneration and diabetic macular edema.

About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel ophthalmic surgical devices and sustained pharmaceutical therapies. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in July 2012 and launched its next-generation iStent inject device in the United States in September 2018. Glaukos is leveraging its platform technologies to build a comprehensive and proprietary portfolio of micro-scale injectable therapies. The company believes the iStent inject, measuring 0.23 mm wide and 0.36 mm long, is the smallest medical device ever approved by the FDA.

Sanofi and Google to develop new healthcare Innovation Lab

healthcare Innovation Lab

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies. The collaboration aims to change how Sanofi develops new treatments and will focus on three key objectives: to better understand patients and diseases, to increase Sanofi’s operational efficiency, and to improve the experience of Sanofi’s patients and customers.

“We stand on the forefront of a new age for biology and human health, with the opportunity to transform healthcare through partnerships with pioneering technology and analytics companies,” says Ameet Nathwani, M.D., Chief Digital Officer, Chief Medical Officer & Executive Vice President, Medical at Sanofi. “Combining Sanofi’s biologic innovations and scientific data with Google’s industry-leading capabilities, from cloud computing to state-of-the-art artificial intelligence, we aspire to give people more control over their health and accelerate the discovery of new therapies.”

“Life sciences companies are looking to data driven, digital innovation to help fuel the creation of accessible healthcare solutions,” said Thomas Kurian, CEO, Google Cloud. “We look forward to collaborating with Sanofi to help accelerate the cycle of healthcare innovation to populations throughout the world.”

The Innovation Lab will develop both scientific and commercial solutions
Sanofi and Google will leverage deep analytics across data sets to better understand key diseases and extract related patient insights. This will enable Sanofi to research and develop more personalized approaches to treatment and identify accompanying technologies to improve health outcomes. The companies will apply technology and analytics on Sanofi’s large real world database to better understand what treatments work for patients. This aims to result in an improved ability to offer personalized treatment advice, thus optimizing patient care and reducing healthcare costs.

Sanofi and Google also plan to apply artificial intelligence (AI) across diverse datasets to better forecast sales and inform marketing and supply chain efforts. Using AI will take into account real-time information as well as geographic, logistic and manufacturing constraints to help the accuracy of these complex activities.

Additionally, Sanofi IT will be modernizing its infrastructure by migrating some existing business applications to Google Cloud Platform (GCP). By leveraging automation, scalability, and agility – along with increases in data and analytic capabilities – Sanofi will accelerate and simplify legacy management, provide easy access to recent technologies and its integration into business plans. The transition to GCP will maximize operational cost efficiency and support business objectives, including the Innovation Lab.

About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Nuance Signs Strategic Partnership with World Renowned Mila Quebec Artificial Intelligence Institute

Nuance Signs Strategic Partnership with World Renowned Mila

Nuance Communications, Inc, a leading provider of Conversational AI and Ambient Intelligence solutions announced it has signed a partnership with Mila, an academic research institution dedicated to advancing machine learning with an intensive focus on deep learning related to language and image processing. This expanded partnership enables Nuance and Mila to collaborate on research, advance cutting-edge work in machine learning, and meaningfully enhance AI applications.

We are excited to enter into this strategic partnership with Mila,” said Joe Petro, Chief Technology Officer, Nuance Communications. “Our research team has been at the forefront of Conversational AI innovation for the last 20 years and this partnership allows us to work more closely with the global academic AI research community to advance the latest in AI innovation and applications.”

We are excited to enter into this strategic partnership with Mila,” said Joe Petro, Chief Technology Officer, Nuance Communications. “Our research team has been at the forefront of Conversational AI innovation for the last 20 years and this partnership allows us to work moreFounded by world-renowned deep learning expert, and recipient of the prestigious 2018 Turing Prize, Yoshua Bengio, Mila is an epicenter of artificial intelligence and machine learning research, seeking to create a space for innovation in artificial intelligence and technology while fostering strong collaboration and knowledge exchange between academic research and innovators in society.

As a market-leader in creating deeply-verticalized AI solutions that deliver real-world results across healthcare, telecommunications, financial services, and automotive industries, Nuance’s global research and development team includes more than 2,800 researchers, speech scientists, and engineers focused on AI research and applications pertaining to speech enhancement, recognition and synthesis, natural language understanding and dialog, biometrics and diagnostic imaging. closely with the global academic AI research community to advance the latest in AI innovation and applications.”

“The future of AI is being shaped by the researchers and technologists who are developing these important systems. Creating an AI ecosystem with important partners like Nuance ensures that we are all working together to create AI that has positive effects on real-world applications,” said Yoshua Bengio, Scientific Director of Mila. “We look forward to working alongside Nuance to continue to advance this critical work.”

As part of the partnership, Nuance will staff an AI lab at Mila’s Montreal-based headquarters, where researchers will partner with Mila interns on projects, and participate in joint research, publications, and knowledge-sharing talks. The lab will serve as an extension of Nuance’s Montreal office, which is one of the company’s key global research sites, and recently named one of “Canada’s Top Employers for Young People,” and one of “Montreal’s Top Employers.” Nuance has long-standing relationships with the academic community and third-party innovators, and the company’s downtown Montreal office has more than 600 employees dedicated to advancing the state-of-the-art in Conversational AI and Ambient Intelligence.

About Nuance Communications, Inc.
Nuance Communications, Inc.is the pioneer and leader in conversational AI innovations that bring intelligence to everyday work and life. The company delivers solutions that understand, analyze and respond to human language to increase productivity and amplify human intelligence. With decades of domain and artificial intelligence expertise, Nuance works with thousands of organizations – in global industries that include healthcare, telecommunications, automotive, financial services, and retail – to create stronger relationships and better experiences for their customers and workforce. For more information, please visit www.nuance.com.

Trademark reference: Nuance and the Nuance logo are registered trademarks or trademarks of Nuance Communications, Inc. or its affiliates in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners.

1...686687688...1,124Page 687 of 1,124

About us

Hospital & healthcare Management is a leading B2B arena designed for the healthcare sector, it allow members to reach both ends of the healthcare facility procurement chain. . . Read More

Subscribe us

System

Resources

Archive Links

Subscribe

Copyright © 2008 - 2026 Hospital & Healthcare Management. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »